() CEO & managing director Dr. Sean Hall speaks with Proactive Investors about the biotech's various research and development programs, focused on delivering therapies for a range of chronic conditions.
"Oncology, specifically pain which is our cannabis area, is a main focal point, it's probably one of our most accelerated areas. Second to that, one of our more recent announcements is in the area of depression where we're looking at increasing efficacy in standard depression medications. Outside that, we have advanced areas of influence in diabetes, chronic kidney disease, ageing... From that we get a pharmaceutical division [that] makes actual drugs that go before registration and we commercialise; [and also] we have a Nutraceutical division that is in-market now," explains Hall.
Trials of Medlab’s NRGBiotic™ product for the treatment of depression are entering Phase II, with Hall describing the research as "a couple of years ahead of its time curve."
Meanwhile, Medlab's cannabis-based research arms are progressing well, with the most-advanced NanaBis™ medication in human trials and licensed under the Therapeutic Goods Administration's (TGA) Special Access Scheme.
